Related Experiment Video
Updated: Aug 19, 2026

Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice
Published on: June 11, 2020
Efficacy of continuous midazolam infusion and mortality in childhood refractory generalized convulsive status
Durgul Ozdemir1, Pamir Gulez, Nedret Uran
1Dokuz Eylul University, School of Medicine, Department of Paediatrics, Izmir, Turkey. durgulozdemir@yahoo.com
Insights
Midazolam infusion effectively controlled refractory generalized convulsive status epilepticus (SE) in children, with a 96% success rate. Treatment safety was confirmed, though mortality correlated with underlying causes of SE.
Area of Science:
- Pediatric Neurology
- Critical Care Medicine
- Pharmacology
Background:
- Status epilepticus (SE) is a neurological emergency often requiring continuous sedation.
- Midazolam infusion is a common treatment for prolonged seizures.
- Refractory generalized convulsive SE in children presents significant management challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of continuous midazolam infusion for treating refractory generalized convulsive SE in pediatric patients.
- To assess the impact of midazolam treatment on seizure control and patient mortality.
- To identify factors influencing treatment outcomes in childhood SE.
Main Methods:
- A cohort of 27 children with refractory generalized convulsive SE was studied.
- Midazolam was administered as an initial bolus followed by a continuous infusion (1-5 microg/kg/min).
- Clinical data, seizure response, and adverse events were systematically recorded.
Main Results:
- Complete seizure control was achieved in 96% of patients within 65 minutes using a mean midazolam infusion rate of 3.1 microg/kg/min.
- No significant adverse effects like hypotension or respiratory depression were observed during midazolam infusion.
- Mortality occurred in 19% of patients, primarily those with acute symptomatic etiologies or progressive encephalopathy.
Conclusions:
- Continuous midazolam infusion demonstrates high efficacy and a favorable safety profile for managing refractory generalized convulsive SE in children.
- The underlying etiology of SE is a critical determinant of treatment response and patient survival.
- Midazolam is a valuable therapeutic option for pediatric refractory SE.
Purpose:
Continuous midazolam infusion is commonly used for the management of status epilepticus (SE). The purpose of this study was to assess the efficacy of midazolam and mortality in childhood refractory generalized convulsive SE.
Methods:
We included 27 children with refractory generalized convulsive SE. Midazolam was given 0.2 mg/kg as bolus, followed by 1-5 microg/kg/min as continuous infusion. Clinical data and response to treatment were recorded for each patient.
Results:
Acute symptomatic SE accounted for 52%, and central nervous system (CNS) infections were the most frequently associated etiologic condition (44%). Complete control of seizures was achieved with midazolam infusion in the 26 (96%) children within 65 min; at a mean midazolam infusion rate of 3.1 microg/kg/min. Adverse effects such as hypotension, bradycardia or respiratory depression did not occur during midazolam infusion. In one (4%) patient with acute meningoencephalitis, SE could not be controlled. Five (19%) patients died; four had acute symptomatic aetiology and one had progressive encephalopathy.
Conclusion:
Midazolam is effective and safe in the control of refractory generalized convulsive SE. The response to treatment and mortality were related to the underlying aetiology.
Related Concept Videos
Parenteral Anesthetics: Overview
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Stages of General Anesthesia
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...